EPIX
ESSA Pharma Inc. [EPIX] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
EPIX Stock Summary
In the News
EPIX Financial details
Company Rating
-
Market Cap
343.29M
Income
-25.81M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
50
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
-11.7
Forward P/E
-
PEG
4.46
P/S
-
P/B
2.13
P/C
-
P/FCF
-15.73
Quick Ratio
42.41
Current Ratio
42.57
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.59
EPS next Y
-
EPS next Q
-
EPS this Y
-25%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
16.67%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-18%
ROE
-17%
ROC
-0.18%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.56-11.67
52W High
-98.17%
52W Low
-89.94%
RSI
17
Rel Volume
39.68
Avg Volume
149.85K
Volume
5.95M
Perf Week
-7.45%
Perf Month
-16.17%
Perf Quarter
-
Perf Half Y
-88.63%
-
-
-
-
Beta
1.694
-
-
Volatility
0%, 0.01%
Prev Close
0%
Price
0.2012
Change
0%
Company Profile
- Volume Average 149.85K
- Market Capitalization 343.29M
- Employee 50
- CEO Dr. David Ross Parkinson M.D.
- Headquarters Vancouver,BC,CA
- IPO Date 2015-03-13
-
Website
https://www.essapharma.com 
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
